Evaluation of a New Glycomacropeptide-Based Protein Substitute in Powdered and Liquid Format in Patients with PKU.

Published version

Published version
Repository DOI

Change log
Authors
Delsoglio, Marta 
Capener, Rebecca 
MacDonald, Anita 
Ashmore, Catherine 
Abstract

(1) Background: Good adherence to a Phe-restricted diet supplemented with an adequate amount of a protein substitute (PS) is important for good clinical outcomes in PKU. Glycomacropeptide (cGMP)-PSs are innovative, palatable alternatives to amino acid-based PSs (AA-PS). This study aimed to evaluate a new cGMP-PS in liquid and powder formats in PKU. (2) Methods: Children and adults with PKU recruited from eight centres were prescribed at least one serving/day of cGMP-PS for 7-28 days. Adherence, acceptability, and gastrointestinal tolerance were recorded at baseline and the end of the intervention. The blood Phe levels reported as part of routine care during the intervention were recorded. (3) Results: In total, 23 patients (powder group, n = 13; liquid group, n = 10) completed the study. The majority assessed the products to be palatable (77% of powder group; 100% of liquid group) and well tolerated; the adherence to the product prescription was good. A total of 14 patients provided blood Phe results during the intervention, which were within the target therapeutic range for most patients (n = 11) at baseline and during the intervention. (4) Conclusions: These new cGMP-PSs were well accepted and tolerated, and their use did not adversely affect blood Phe control.

Description

Peer reviewed: True


Funder: Nutricia Ltd.

Keywords
PKU, glycomacropeptide, phenylketonuria, protein substitute, Adult, Child, Humans, Powders, Caseins, Peptide Fragments, Dietary Supplements, Cyclic GMP
Journal Title
Nutrients
Conference Name
Journal ISSN
2072-6643
2072-6643
Volume Title
15
Publisher
MDPI AG